1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.2.1 INCLUSIONS & EXCLUSIONS 35
1.3 STUDY SCOPE 37
1.3.1 MARKETS COVERED 37
1.3.2 REGIONS COVERED 38
1.3.3 YEARS CONSIDERED 38
1.3.4 CURRENCY CONSIDERED 38
1.4 KEY STAKEHOLDERS 39
1.5 SUMMARY OF CHANGES 39
1.6 RECESSION IMPACT 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 1 RESEARCH DESIGN 41
2.1.1 SECONDARY RESEARCH 42
2.1.2 PRIMARY RESEARCH 43
2.1.2.1 Key data from primary sources 43
2.1.2.2 Key industry insights 44
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 44
FIGURE 3 BREAKDOWN OF PRIMARIES 45
2.2 MARKET SIZE ESTIMATION 45
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 46
2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION 46
2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION 47
FIGURE 5 POINT-OF-CARE DIAGNOSTICS MARKET: MARKET SIZE ESTIMATION METHODOLOGY 48
2.2.3 PRIMARY RESEARCH VALIDATION 48
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 49
FIGURE 6 DATA TRIANGULATION METHODOLOGY 49
2.4 RESEARCH LIMITATIONS 50
2.5 RECESSION IMPACT ANALYSIS 51
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 51
3 EXECUTIVE SUMMARY 52
FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 52
FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2023 VS. 2028 (USD MILLION) 53
FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2023 VS. 2028 (USD MILLION) 53
FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 54
FIGURE 11 GEOGRAPHIC SNAPSHOT OF POINT-OF-CARE DIAGNOSTICS MARKET 55
4 PREMIUM INSIGHTS 56
4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW 56
FIGURE 12 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 56
4.2 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 57
FIGURE 13 INFECTIOUS DISEASE TESTING PRODUCTS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 57
4.3 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (2022) 58
FIGURE 14 OTC TESTING PRODUCTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58
4.4 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2023 VS. 2028 58
FIGURE 15 LATERAL FLOW ASSAYS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58
4.5 POINT-OF-CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 17 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
5.2.1 DRIVERS 61
5.2.1.1 Rising incidence of infectious diseases 61
FIGURE 18 REGIONAL INCIDENCE OF HIV (2022) 61
5.2.1.2 Increasing prevalence of target conditions 62
5.2.1.3 Favorable government initiatives for POC testing 62
5.2.1.4 Rising number of CLIA-waived POC tests 63
TABLE 2 RECENT WAIVERS FOR PRODUCTS 63
5.2.2 RESTRAINTS 64
5.2.2.1 Pricing pressure on POC manufacturers 64
5.2.2.2 Stringent regulatory approval process for product commercialization 64
5.2.3 OPPORTUNITIES 65
5.2.3.1 High growth potential of emerging markets 65
5.2.3.2 Decentralization of healthcare 65
5.2.3.3 Innovative product development 66
5.2.4 CHALLENGES 66
5.2.4.1 Inadequate standardization with centralized lab methods 66
5.2.4.2 Limited awareness in emerging markets 67
5.2.4.3 Premium pricing of novel platforms 67
5.3 TECHNOLOGY ANALYSIS 68
5.3.1 POC TESTS WITH MULTIPLEXING CAPABILITIES 68
5.3.2 STROKE/CARDIAC MARKERS 68
5.3.3 THYROID TESTING 68
5.3.4 DNA TESTING 69
5.3.5 ENDOCRINE TESTING 69
5.3.6 RESPIRATORY DIAGNOSTICS 69
5.4 REGULATORY LANDSCAPE 70
TABLE 3 REGULATORY BODIES AND GOVERNMENT AGENCIES 70
5.4.1 KEY REGULATORY GUIDELINES 70
5.4.1.1 US 70
FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES 71
5.4.1.2 Canada 72
FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES 72
5.4.1.3 Europe 72
FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 73
5.4.1.4 Japan 74
FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 74
5.4.1.5 China 74
TABLE 4 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 75
5.4.1.6 India 75
FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES 75
5.4.1.7 Brazil 76
FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 76
5.5 VALUE CHAIN ANALYSIS 77
FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION & DISTRIBUTION STAGES 77
5.6 SUPPLY CHAIN ANALYSIS 78
5.6.1 PROMINENT COMPANIES 78
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 78
5.6.3 END USERS 78
FIGURE 26 SUPPLY CHAIN ANALYSIS 79
5.6.4 PRICING ANALYSIS 79
TABLE 5 AVERAGE SELLING PRICE OF LEADING PRODUCTS, BY KEY PLAYER (USD) 79
FIGURE 27 AVERAGE SELLING PRICE OF TOP 2 LEADING PRODUCTS, BY KEY PLAYER 80
5.6.4.1 Average selling price trend 80
TABLE 6 AVERAGE PRICE OF GLUCOSE MONITORING & CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022 (USD) 80
TABLE 7 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022 (USD) 81
TABLE 8 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2022 (USD) 81
5.7 PORTER’S FIVE FORCES ANALYSIS 82
TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 82
5.7.1 BARGAINING POWER OF BUYERS 82
5.7.2 BARGAINING POWER OF SUPPLIERS 82
5.7.3 THREAT OF NEW ENTRANTS 82
5.7.4 THREAT OF SUBSTITUTES 83
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.8 TRADE DATA 83
TABLE 10 IMPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION) 83
TABLE 11 EXPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION) 84
5.9 REIMBURSEMENT SCENARIO 84
TABLE 12 KEY MEDICARE CLINICAL LAB FEE SCHEDULE (CLFS) CODES FOR COVID-19 TESTING 84
TABLE 13 MEDICARE HCPCS CODES FOR HIV TESTING 85
5.10 PATENT ANALYSIS 85
FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012–DECEMBER 2023) 85
5.10.1 ECOSYSTEM/MARKET MAP 86
FIGURE 29 ANALYSIS OF PARENT MARKET: IN VITRO DIAGNOSTICS MARKET 86
5.10.2 KEY CONFERENCES & EVENTS 86
TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET: LIST OF KEY CONFERENCES & EVENTS (2023−2024) 86
5.11 CASE STUDY ANALYSIS 87
5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I 87
TABLE 15 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS 87
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 88
FIGURE 30 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 88
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 88
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE TESTING KITS & INSTRUMENTS 88
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR POINT-OF-CARE TESTING KITS AND INSTRUMENTS (%) 89
5.14 BUYING CRITERIA 89
FIGURE 32 KEY BUYING CRITERIA FOR POINT-OF-CARE TESTING KITS & INSTRUMENTS 89
TABLE 17 KEY BUYING CRITERIA FOR POC PRODUCTS 89
6 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 90
6.1 INTRODUCTION 91
TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 91
6.2 OTC TESTING PRODUCTS 91
6.2.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET 91
TABLE 19 OTC TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 92
6.3 PRESCRIPTION-BASED TESTING PRODUCTS 92
6.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 92
TABLE 20 PRESCRIPTION-BASED TESTING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 93
7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM 94
7.1 INTRODUCTION 95
TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 95
7.2 LATERAL FLOW ASSAYS 95
7.2.1 RISING ADOPTION OF TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET 95
TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2021–2028 (USD MILLION) 96
7.3 IMMUNOASSAYS 96
7.3.1 UTILIZATION IN INFECTIOUS DISEASE TESTING TO SUPPORT MARKET GROWTH 96
TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION) 97
7.4 MICROFLUIDICS 97
7.4.1 GROWING TREND OF MINIATURIZATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET 97
TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2021–2028 (USD MILLION) 98
7.5 DIPSTICKS 98
7.5.1 QUALITATIVE ANALYSIS OF MEDICAL CONDITIONS TO SUPPORT MARKET GROWTH 98
TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2021–2028 (USD MILLION) 99
7.6 MOLECULAR DIAGNOSTICS 99
TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2021–2028 (USD MILLION) 100
TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 100
7.6.1 RT-PCR 100
7.6.1.1 Rising cases of COVID-19 to boost demand 100
TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION) 101
7.6.2 INAAT 101
7.6.2.1 Cost benefits of INAAT to propel segment growth 101
TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION) 102
7.6.3 OTHER TECHNOLOGIES 102
TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 102
8 POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE 103
8.1 INTRODUCTION 104
TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 104
8.2 BLOOD SAMPLES 104
8.2.1 HIGH UTILIZATION IN DISEASE DETECTION TO DRIVE MARKET 104
TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2021–2028 (USD MILLION) 104
8.3 URINE SAMPLES 105
8.3.1 INCREASING PREVALENCE OF KIDNEY DISORDERS AND WIDE RANGE OF DIAGNOSTIC TARGETS TO BOOST DEMAND 105
TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2021–2028 (USD MILLION) 105
8.4 NASAL & OROPHARYNGEAL SWABS 105
8.4.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET 105
TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2021–2028 (USD MILLION) 106
8.5 OTHER SAMPLES 106
TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION) 106
9 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 107
9.1 INTRODUCTION 108
TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108
9.2 GLUCOSE MONITORING PRODUCTS 109
TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 110
9.2.1 STRIPS 110
9.2.1.1 Ability to provide single-use measurement testing to drive market 110
TABLE 39 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2021–2028 (USD MILLION) 110
9.2.2 METERS 111
9.2.2.1 Ability to adjust therapeutic regimens daily to support market growth 111
TABLE 40 GLUCOSE MONITORING METERS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
9.2.3 LANCETS & LANCING DEVICES 111
9.2.3.1 Provision of multiple depth penetration settings to boost demand 111
TABLE 41 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 112
9.3 COVID-19 TESTING PRODUCTS 112
9.3.1 RISING UPTAKE OF RT-PCR RAPID TESTS TO BOOST DEMAND 112
TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 113
9.4 CARDIOMETABOLIC MONITORING PRODUCTS 113
TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 114
9.4.1 CARDIAC MARKER TESTING PRODUCTS 114
9.4.1.1 Rising government initiatives for CVD research to drive market 114
TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 114
9.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 115
9.4.2.1 Technological advancements in monitoring products to support market growth 115
TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 115
9.4.3 HBA1C TESTING PRODUCTS 115
9.4.3.1 Favorable clinical outcomes with long-term monitoring to drive market 115
TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 116
9.5 INFECTIOUS DISEASE TESTING PRODUCTS 117
TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 118
9.5.1 HIV TESTING PRODUCTS 118
9.5.1.1 Rising prevalence of HIV to drive market 118
TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 118
9.5.2 RESPIRATORY INFECTION TESTING PRODUCTS 119
9.5.2.1 Rising incidence of respiratory infections to drive market 119
TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 119
9.5.3 HEPATITIS C TESTING PRODUCTS 119
9.5.3.1 Increasing prevalence of viral hepatitis to support market growth 119
TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 120
9.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 120
9.5.4.1 High incidence of UTIs and surgical-site infections to boost demand 120
TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 121
9.5.5 INFLUENZA TESTING PRODUCTS 121
9.5.5.1 Ability to identify A & B viral nucleoprotein antigens to drive market 121
TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 121
9.5.6 TROPICAL DISEASE TESTING PRODUCTS 122
9.5.6.1 Rising incidence of malaria and dengue to support market growth 122
TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 122
9.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 122
TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 123
9.5.7.1 Syphilis testing products 123
9.5.7.1.1 Introduction of rapid tests to boost demand 123
TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 124
9.5.7.2 Human papillomavirus (HPV) testing products 124
9.5.7.2.1 Rising uptake of HPV diagnostics and RT-PCR to support market growth 124
TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 125
9.5.7.3 Chlamydia trachomatis testing products 125
9.5.7.3.1 Growing awareness of STI detection to boost demand 125
TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 126
9.5.7.4 Herpes simplex virus (HSV) testing products 126
9.5.7.4.1 Increasing incidence of HSV to support market growth 126
TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 126
9.5.8 TUBERCULOSIS 127
9.5.8.1 Rising prevalence of TB in underserved areas to support market growth 127
TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (USD MILLION) 127
9.5.9 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS 127
9.5.9.1 Rising cases among hospitalized patients to boost demand 127
TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR CDI, BY REGION, 2021–2028 (USD MILLION) 128
9.5.10 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 128
TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 128
9.6 COAGULATION MONITORING PRODUCTS 129
TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 130
9.6.1 PT/INR TESTING PRODUCTS 130
9.6.1.1 Ability to detect blood clots to support market growth 130
TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 130
9.6.2 ACT/APTT TESTING PRODUCTS 131
9.6.2.1 Rising cases of dialysis and ESRD to boost demand 131
TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 131
9.7 PREGNANCY & FERTILITY TESTING PRODUCTS 131
TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 132
9.7.1 PREGNANCY TESTING PRODUCTS 132
9.7.1.1 Growing preference for home care testing to drive market 132
TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 132
9.7.2 FERTILITY TESTING PRODUCTS 133
9.7.2.1 Growing focus on family planning to boost demand 133
TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 133
9.8 TUMOR/CANCER MARKER TESTING PRODUCTS 133
9.8.1 INCREASING INCIDENCE OF CANCER AND RISING UPTAKE OF IMMUNOASSAYS TO PROPEL MARKET 133
TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 134
9.9 URINALYSIS TESTING PRODUCTS 134
9.9.1 HIGH INCIDENCE OF RECURRENT UTIS TO DRIVE MARKET 134
TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 135
9.10 CHOLESTEROL TESTING PRODUCTS 135
9.10.1 RISING OBESITY LEVELS AND INCIDENCE OF CVD TO BOOST DEMAND 135
TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 135
9.11 HEMATOLOGY TESTING PRODUCTS 136
9.11.1 PREFERENCE FOR LABORATORY-BASED TESTS TO RESTRAIN MARKET 136
TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2021–2028(USD MILLION) 136
9.12 DRUGS-OF-ABUSE TESTING PRODUCTS 136
9.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET 136
TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 137
9.13 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS 137
9.13.1 RISING CASES OF THYROID TO BOOST DEMAND 137
TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 137
9.14 FECAL OCCULT TESTING PRODUCTS 138
9.14.1 INCREASING AWARENESS ON EARLY DISEASE DETECTION TO SUPPORT MARKET GROWTH 138
TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 138
9.15 OTHER PRODUCTS 138
TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 139
10 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER 140
10.1 INTRODUCTION 141
TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 141
10.2 CLINICAL LABORATORIES 141
10.2.1 IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST DEMAND 141
TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 142
10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES 142
10.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE TO DRIVE MARKET 142
TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION) 143
10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS 143
10.4.1 ABILITY TO SUPPORT CHRONIC DISEASE MANAGEMENT TO BOOST DEMAND 143
TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2021–2028 (USD MILLION) 143
10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 144
10.5.1 RAPID RESULTS AND END USERS OF POC DIAGNOSTICS 144
TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2021–2028 (USD MILLION) 144
10.6 HOME CARE SETTINGS AND SELF-TESTING 145
10.6.1 GROWING INCLINATION TOWARDS REMOTE-BASED CARE TO DRIVE MARKET 145
TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2021–2028 (USD MILLION) 145
10.7 OTHER END USERS 146
TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 146
11 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 147
11.1 INTRODUCTION 148
TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 148
11.2 NORTH AMERICA 148
11.2.1 NORTH AMERICA: RECESSION IMPACT 148
FIGURE 33 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 149
TABLE 89 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 90 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150
TABLE 91 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 92 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 93 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 94 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 95 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 96 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 153
TABLE 97 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 154
TABLE 98 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 154
TABLE 99 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 155
11.2.2 US 155
11.2.2.1 Favorable government support and medical reimbursements to boost demand 155
TABLE 100 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156
11.2.3 CANADA 157
11.2.3.1 Rising incidence of diabetes and cancer to support market growth 157
TABLE 101 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 158
11.3 EUROPE 159
11.3.1 EUROPE: RECESSION IMPACT 159
TABLE 102 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 103 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 160
TABLE 104 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 105 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 106 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 107 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 108 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 109 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 163
TABLE 110 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 163
TABLE 111 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 164
TABLE 112 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 164
11.3.2 GERMANY 165
11.3.2.1 Rising demand for innovative technologies to propel market 165
TABLE 113 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 166
11.3.3 FRANCE 166
11.3.3.1 Growing public-private collaborations for product development to drive market 166
TABLE 114 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167
11.3.4 UK 168
11.3.4.1 Growing number of accredited diagnostic & hospital laboratories to propel market 168
TABLE 115 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169
11.3.5 ITALY 169
11.3.5.1 Increasing adoption of infectious disease diagnostics to drive market 169
TABLE 116 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 170
11.3.6 SPAIN 170
11.3.6.1 Rising incidence of chronic diseases to support market growth 170
TABLE 117 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 171
11.3.7 REST OF EUROPE 171
TABLE 118 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172
11.4 ASIA PACIFIC 173
11.4.1 ASIA PACIFIC: RECESSION IMPACT 173
FIGURE 34 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 174
TABLE 119 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 120 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176
TABLE 121 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 122 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 123 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 124 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 125 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 126 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 179
TABLE 127 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 179
TABLE 128 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 180
TABLE 129 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 180
11.4.2 JAPAN 181
11.4.2.1 Availability of advanced rapid flu tests to drive market 181
TABLE 130 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 182
11.4.3 CHINA 182
11.4.3.1 Rising incidence of infectious diseases to drive market 182
TABLE 131 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 183
11.4.4 INDIA 184
11.4.4.1 High burden of chronic diseases to propel market 184
TABLE 132 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 185
11.4.5 AUSTRALIA 185
11.4.5.1 Increasing research investments for next-gen POC devices to fuel market 185
TABLE 133 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION 186
11.4.6 SOUTH KOREA 187
11.4.6.1 Growing awareness about advanced POC devices to boost demand 187
TABLE 134 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 187
11.4.7 REST OF ASIA PACIFIC 188
TABLE 135 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 189
11.5 LATIN AMERICA 190
11.5.1 LATIN AMERICA: RECESSION IMPACT 190
TABLE 136 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 137 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 191
TABLE 138 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 139 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 140 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 141 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 142 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 143 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 193
TABLE 144 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 194
TABLE 145 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 194
TABLE 146 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 195
11.5.2 BRAZIL 195
11.5.2.1 Rising prevalence of diabetes to support market growth 195
TABLE 147 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 196
11.5.3 MEXICO 197
11.5.3.1 Rising incidence of cancer to drive market 197
TABLE 148 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 197
11.5.4 REST OF LATIN AMERICA 198
TABLE 149 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 198
11.6 MIDDLE EAST & AFRICA 199
11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 199
TABLE 150 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 151 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 200
TABLE 152 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 153 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 154 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 155 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 156 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 157 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION) 202
TABLE 158 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION) 203
TABLE 159 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 203
TABLE 160 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION) 204
11.6.1.1 GCC Countries 204
11.6.1.1.1 Improvements in healthcare infrastructure to drive market 204
TABLE 161 GCC COUNTRIES: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205
11.6.2 REST OF MIDDLE EAST & AFRICA 205
TABLE 162 REST OF AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 206
TABLE 163 REST OF MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 207
12.1 INTRODUCTION 208
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 208
FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET 209
12.3 REVENUE SHARE ANALYSIS 210
FIGURE 36 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET (2022) 210
12.4 MARKET SHARE ANALYSIS 211
FIGURE 37 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 211
12.5 COMPANY EVALUATION MATRIX 212
12.5.1 STARS 212
12.5.2 EMERGING LEADERS 212
12.5.3 PERVASIVE PLAYERS 212
12.5.4 PARTICIPANTS 212
FIGURE 38 COMPANY EVALUATION MATRIX 213
12.5.5 COMPANY FOOTPRINT 214
12.5.5.1 Product & regional footprint 214
TABLE 164 OVERALL FOOTPRINT 214
TABLE 165 PRODUCT FOOTPRINT 215
TABLE 166 REGIONAL FOOTPRINT 216
12.6 START-UP/SME EVALUATION MATRIX 217
12.6.1 PROGRESSIVE COMPANIES 217
12.6.2 RESPONSIVE COMPANIES 217
12.6.3 DYNAMIC COMPANIES 217
12.6.4 STARTING BLOCKS 217
FIGURE 39 START-UP/SME EVALUATION MATRIX 218
12.6.5 COMPETITIVE BENCHMARKING 219
TABLE 167 POINT-OF-CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 219
12.7 COMPETITIVE SCENARIO 220
12.7.1 PRODUCT LAUNCHES & APPROVALS 220
TABLE 168 POINT-OF-CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–NOVEMBER 2023) 220
12.7.2 DEALS 221
TABLE 169 POINT-OF-CARE DIAGNOSTICS MARKET: DEALS (JANUARY 2020–NOVEMBER 2023) 221
12.7.3 OTHER DEVELOPMENTS 222
TABLE 170 POINT-OF-CARE DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020–NOVEMBER 2023) 222
13 COMPANY PROFILES 223
13.1 KEY PLAYERS 223
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 ABBOTT LABORATORIES 223
TABLE 171 ABBOTT LABORATORIES: COMPANY OVERVIEW 223
FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 224
13.1.2 F. HOFFMANN-LA ROCHE LTD. 228
TABLE 172 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 228
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 229
13.1.3 SIEMENS HEALTHINEERS 233
TABLE 173 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 233
FIGURE 42 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023) 234
13.1.4 QUIDELORTHO CORPORATION 239
TABLE 174 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 239
FIGURE 43 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 240
13.1.5 DANAHER CORPORATION 246
TABLE 175 DANAHER CORPORATION: COMPANY OVERVIEW 246
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 247
13.1.6 BECTON, DICKINSON AND COMPANY 252
TABLE 176 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 252
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 253
13.1.7 THERMO FISHER SCIENTIFIC INC. 256
TABLE 177 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 256
FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 257
TABLE 178 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 259
13.1.8 BIOMÉRIEUX 264
TABLE 179 BIOMÉRIEUX : COMPANY OVERVIEW 264
FIGURE 47 BIOMÉRIEUX : COMPANY SNAPSHOT (2022) 265
13.1.9 CHEMBIO DIAGNOSTICS, INC. 271
TABLE 180 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW 271
FIGURE 48 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022) 272
13.1.10 EKF DIAGNOSTICS HOLDINGS PLC 275
TABLE 181 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 275
FIGURE 49 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2022) 276
13.1.11 TRINITY BIOTECH PLC 279
TABLE 182 TRINITY BIOTECH PLC: COMPANY OVERVIEW 279
FIGURE 50 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2022) 280
13.1.12 WERFEN, S.A. 282
TABLE 183 WERFEN: COMPANY OVERVIEW 282
FIGURE 51 WERFEN, S.A.: COMPANY SNAPSHOT (2022) 283
13.1.13 NOVA BIOMEDICAL 286
TABLE 184 NOVA BIOMEDICAL: COMPANY OVERVIEW 286
13.1.14 PTS DIAGNOSTICS 289
TABLE 185 PTS DIAGNOSTICS: COMPANY OVERVIEW 289
13.1.15 SEKISUI DIAGNOSTICS 291
TABLE 186 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 291
13.1.16 EUROLYSER DIAGNOSTICA GMBH 294
TABLE 187 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW 294
13.1.17 RESPONSE BIOMEDICAL 296
TABLE 188 RESPONSE BIOMEDICAL: COMPANY OVERVIEW 296
13.1.18 ALFA SCIENTIFIC DESIGNS, INC. 298
TABLE 189 ALFA SCIENTIFIC DESIGNS, INC: COMPANY OVERVIEW 298
13.1.19 BODITECH MED INC. 299
TABLE 190 BODITECH MED INC.: COMPANY OVERVIEW 299
13.1.20 BTNX INC. 301
TABLE 191 BTNX INC.: COMPANY OVERVIEW 301
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 302
13.2.1 LIFESCAN IP HOLDINGS, LLC 302
13.2.2 ASCENSIA DIABETES CARE HOLDINGS AG 303
13.2.3 FLUXERGY 304
13.2.4 PRECISION BIOSENSOR, INC. 305
13.2.5 ACON LABORATORIES, INC. 306
13.2.6 A. MENARINI DIAGNOSTICS S.R.L. 307
13.2.7 ORASURE TECHNOLOGIES, INC. 309
13.2.8 MANKIND PHARMA 310
13.2.9 GRIFOLS, S.A. 311
13.2.10 DIASORIN S.P.A. 312
14 APPENDIX 314
14.1 DISCUSSION GUIDE 314
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 319
14.3 CUSTOMIZATION OPTIONS 321
14.4 RELATED REPORTS 321
14.5 AUTHOR DETAILS 322
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
